SU 12662

Known as: SU-12662, SU12662 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2017
02420062017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Interpatient variability in the pharmacokinetics (PK) of sunitinib is high. Single nucleotide polymorphisms (SNPs) in PK… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 3
Is this relevant?
2014
2014
Introduction Sunitinib is a multikinase inhibitor active in various cancers types including renal cancers and endocrine tumors… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2014
2014
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that acts against receptors for vascular endothelial growth… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
Is this relevant?
2013
2013
Sunitinib commonly exhibits dose-limiting dermatological toxicities (DTs) that adversely affect health-related quality of life… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2012
2012
CONTEXT Treatment of refractory adrenocortical carcinoma (ACC) is not established. Animal experiments pointed toward adrenal… (More)
Is this relevant?
2010
2010
A pharmacokinetic/pharmacodynamic (PK/PD) study of the tyrosine kinase inhibitor sunitinib was conducted in 12 healthy volunteers… (More)
Is this relevant?
2010
2010
This phase I, open-label, single-dose study evaluates the effects of severe renal impairment and end-stage renal disease (ESRD… (More)
  • table I
  • figure 1
  • figure 2
  • figure 3
  • table II
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for advanced renal cell carcinoma and… (More)
  • table 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2009
2009
This study evaluated the effect of hepatic impairment on the pharmacokinetics of sunitinib and its active metabolite, SU12662… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Sunitinib, an oral multitargeted tyrosine kinase inhibitor that inhibits VEGFR, PDGFR, FLT3, KIT, and RET, is currently approved… (More)
  • table 1
  • table 3
  • table 2
  • table 4
  • figure 1
Is this relevant?